Research in Molecular Medicine
Research in Molecular Medicine
Res Mol Med (RMM)
Medical Sciences
http://rmm.mazums.ac.ir
1
admin
2322-1348
2322-133X
10.29252/rmm
en
jalali
1391
11
1
gregorian
2013
2
1
1
1
online
1
fulltext
en
Resistance to HER2-targeted therapy
ايمونولوژي
Immunology
پژوهشي
Research
<p><br>
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug acquire resistance to it and experience tumor recurrence within 1 year. Several molecular and cellular mechanisms underlying the resistance to trastuzumab have been proposed. In this review, first, we provide a brief history leading to production of trastuzumab. Also we consider the cellular and molecular antitumor effects of trastuzumab and then, we discuss the mechanisms underlying trastuzumab resistance in four levels.</p>
Trastuzumab, ErbB, Breast cancer, Mechanisms of action, Resistance
1
9
http://rmm.mazums.ac.ir/browse.php?a_code=A-10-589-1&slc_lang=en&sid=1
Reza
Valadan
10031947532846005781
10031947532846005781
No
Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Alireza
Rafiei
rafiei1710@gmail.com
10031947532846005782
10031947532846005782
Yes
Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Mohsen
Tehrani
10031947532846005783
10031947532846005783
No
Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Forough
Nejatollahi
10031947532846005784
10031947532846005784
No
Recombinant antibody laboratory, Department of Immunology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran